RxDoctor Payments Data

Mary Beth Hood

Family · Spartanburg, SCNPI 1275080723

Payments from drug & device makers

$3,249in general payments, 2019–2025

Across 214 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$457
  • Esperion Therapeutics, Inc.$342
  • AstraZeneca$335
  • Amarin Pharma, Inc.$305
  • Takeda Pharmaceuticals U.S.A., Inc.$219
  • Bayer$206
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$3,249100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,249 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$214,499
Medicare patients
204
Services billed
2,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$74,129
XareltoRivaroxaban40$18,832
MyrbetriqMirabegron37$16,430
FarxigaDapagliflozin Propanediol36$13,457
Breo ElliptaFluticasone/Vilanterol23$9,916
GemtesaVibegron17$7,865
LinzessLinaclotide12$6,845
Atorvastatin Calcium202$3,311
Methenamine Hippurate43$3,111
Potassium Chloride160$2,803
Rosuvastatin Calcium68$2,480
Duloxetine Hcl37$2,397
Omeprazole124$2,257
Levothyroxine Sodium148$2,101
Divalproex Sodium35$1,937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$74,129145 claims
Johnson & JohnsonXarelto$30$18,83240 claims
AstraZenecaFarxiga$335$13,45736 claims
GSKBreo Ellipta$104$9,91623 claims
AbbVieLinzess$457$6,84512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.

Other family in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →